
    
      To compare the two treatment groups with the goal of achieving HIV-1 RNA levels less than 50
      copies/mL at week 48.

      To compare the safety, efficacy and tolerability of the two treatment regimens through 144
      weeks of drug exposure.

      To evaluate the long-term efficacy, safety and tolerability of tenofovir DF in combination
      with lamivudine and efavirenz through approximately 336 weeks of drug exposure.
    
  